
Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic
Key Takeaways
- Pain severity independently predicted positive screening in multivariable modeling, supporting symptom burden as a pragmatic triage signal during dermatology encounters.
- Post-implementation screening was associated with a statistically significant increase in PsA diagnoses compared with pre-implementation clinic rates, reinforcing operational value despite single-center design.
In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.
Among patients with psoriasis (PsO) at an outpatient dermatology clinic, 61.5% screened positive for psoriatic arthritis (PsA), according to a prospective study published in the Journal of Drugs in Dermatology.1 The authors concluded that implementing routine PsA screening in dermatology practice markedly increased PsA detection.
PsA affects up to 30% of patients with PsO and can lead to irreversible joint damage without early intervention, the authors wrote. Yet up to 40% of dermatology providers do not routinely screen patients with PsO for PsA. Barriers include limited time during visits, lack of training in screening tools, and uncertainty about next steps.
How Many Patients With Psoriasis Screened Positive for PsA?
Over a 3-month period, 72 of 117 adults with dermatologist-confirmed PsO (61.5%) screened positive on the Psoriasis Epidemiology Screening Tool (PEST). The single-center, nonrandomized study was conducted in Southeast Tennessee. Overall, 54.7% of patients were female, and 92.4% were White. Pain severity was the only significant predictor of a positive screen (P <.001) in a logistic regression that included demographic variables.
Before PEST implementation, 16 PsA cases were diagnosed among 1261 total patients seen at the clinic from January 2021 to March 2022. The authors reported a statistically significant difference in PsA detection after PEST implementation (P <.001). They also noted that overall PsA prevalence among patients with PsO is 20%.
Does a Mediterranean Diet Reduce Pain With Biologic Therapy?
Guselkumab combined with a Mediterranean diet was associated with the greatest reduction in pain scores at 1 month. Of the patients who screened positive, 71 enrolled in the treatment phase and chose biologic therapy alone or with the diet. Medication selection was determined by provider experience and insurance coverage.
Among the 56 patients analyzed, mean pain scores on a 0-to-10 scale fell by 3.13 points with guselkumab plus the diet (n = 24), 3.00 points with secukinumab alone (n = 7), 2.64 points with secukinumab plus the diet (n = 11), and 1.86 points with guselkumab alone (n = 14). Post hoc testing showed a significant difference only between guselkumab plus the diet and guselkumab alone (P = .01). Mean baseline pain ranged from 4.18 to 6.00 across groups. Of 47 patients willing to follow the diet, 25% were deemed noncompliant and excluded, leaving 35 in the intervention arm. The authors said noncompliance, lack of randomization, and absence of blinding introduced potential bias. They also cited a small sample size and a predominantly White population. Insurance formularies and sample availability also led to a disproportionately larger guselkumab group and potentially more favorable outcomes, they said.
Can PsA Screening Work Across Multiple Dermatology Clinics?
A 27-month quality improvement initiative integrated the PEST and the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) into the electronic medical record at 26 dermatology clinics.2 Among 6473 patients without a PsA diagnosis, 37.2% completed the PEST, and 12.5% scored 3 or higher and completed the PsAID-12, which was also completed by patients already diagnosed with PsA.
Of those who took the PsAID-12, 24.3% scored above 4. Among them, 24.7% were referred to rheumatology, and 44.4% subsequently received a PsA diagnosis. The investigators stated that the initiative demonstrated the feasibility of the clinical framework. The current study's authors said future research should examine PsA screening integrated into the electronic medical record and dietary interventions over longer follow-up.1
References
- Czerkasij V, Romanelli S, Childs B, et al. Implementing psoriatic arthritis screening and dietary interventions in dermatology practice: a prospective clinical study. J Drugs Dermatol. 2026;25(11):1033-1038. doi:10.36849/JDD.9910
- Romanelli S, Ball GD, Hamade H, et al. Streamlining psoriatic arthritis screening and management using the IDEOM clinical framework: a quality improvement initiative. J Drugs Dermatol. 2025;24(8):777-781. doi:10.36849/JDD.9210
Related to this article








